Why BGPT?
logo

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what falsifiable science actually supports before you trust the answer.

Press Enter ↵ to search evidence


     Quick Explanation



    Michael Köttgen is a strong, productive kidney-genetics and cell-biology scientist (h-index 33, ~5,237 citations, 85 works) whose landmark 2009 ABCG2 urate-transporter paper combined mechanistic functional work with population genetics in a model that others have followed .


     Long Explanation



    Scientific Profile and Citation Impact

    Michael Köttgen (ORCID 0000-0003-2406-5039) has 85 indexed works with ~5,237 citations and an h-index of 33 (OpenAlex; Scopus-consistent metrics: h-index 31, ~4,475 citations, 71 papers). Citation flow is sustained and recent — roughly 300–385 citations per year from 2020–2026 — indicating continued relevance rather than reliance on legacy citations alone. Topic profiles concentrate in biology, cell biology, kidney, and genetics.

    His flagship contribution, the 2009 PNAS paper, demonstrates gene function behind a GWAS signal: ABCG2 mediates urate efflux (75.5% reduction in urate accumulation in ABCG2-expressing oocytes vs. controls), localizes apically in polarized LLC-PK1 cells, and the common Q141K variant reduces transport by 54% . Population genetics in ARIC (10,902 white and 3,881 black participants for urate) gave P trend = 3×10⁻³⁰ (whites) and 7×10⁻⁴ (blacks), with an OR of 1.68 per T allele for gout and an estimated 10% population-attributable risk in whites . This functional-plus-population design is a template for causal GWAS follow-up. Limitations to note: gout was self-reported, the black cohort had only 3% minor allele frequency (requiring genotype pooling), and functional work relied on heterologous oocyte and porcine cell models rather than human proximal tubule.

    Methodological Breadth and Rigor

    The publication list spans ion-channel biology (TRPP2, TRPV4), polycystic kidney disease mechanisms (DNAJB11 co-chaperones, 3D tubulogenesis assays, deep-learning image quantification), metabolite GWAS in Nature Genetics, and — most recently — computational cell-type assignment (CellMatchR with TabPFN machine learning, 2026) . The 2026 paper shows healthy self-critical practice: cross-dataset accuracy is honestly reported as modest (~56–59%), negative controls were used (10% false positives with Spearman, 0% with ML), and a conflict of interest (TabPFN co-founder) is disclosed. Earlier URAT1 GWAS work in African Americans extended the urate-transporter genetics program across ancestries .

    Strengths, Blindspots, and Uncertainty

    • Strengths: mechanism-first GWAS validation (ABCG2), methodological innovation (3D tubulogenesis, deep-learning quantification, TabPFN assignment), cross-species and cross-ancestry scope, transparent limitations and COI disclosure.
    • Blindspots: functional transporter work often uses heterologous models (Xenopus oocytes, LLC-PK1) rather than native human tubule; the 2026 CellMatchR framework is contingent on reference datasets with limited nephron-segment coverage and inter-reference variability; h-index metrics can undercount or overcount via name disambiguation.
    • What would change this assessment: failure of Q141K to show normal-vs-reduced transport in human kidney tissue, or CellMatchR assignments failing on unseen references, would weaken the respective claims.

    Overall: a rigorous, mechanistically oriented, methodologically adaptive kidney scientist whose strongest work bridges gene function and population genetics with quantified, reproducible evidence. Confidence: high for career metrics and ABCG2 findings; moderate for newer computational work given limited independent replication.



    Feedback:    

    Updated: November 17, 2026

     BGPT Author Review



    Scientific Quality

    80%

    Köttgen's hallmark is combining GWAS signals with direct functional validation (ABCG2 urate efflux, Q141K loss-of-function, ARIC association with P=3e-30), a causal-inference standard few authors meet. Strong track record across ion channels, PKD, and metabolite genetics; h-index 33 with sustained recent citations. Weakened somewhat by reliance on heterologous models (oocytes, LLC-PK1) rather than native human tissue, self-reported gout outcomes, and modest cross-dataset accuracy in the newest computational work. No major red flags; COI disclosure is transparent.



    Communication Quality

    70%

    Papers report methods, controls, and quantitative statistics clearly (e.g., explicit oocyte sample sizes, P values, attributable-risk calculations). The 2026 CellMatchR paper openly reports cross-dataset accuracy limits, which aids reader calibration. However, work spans highly technical subfields without obvious popularization or unifying narrative accessible to non-specialists.



    Author Novelty

    80%

    The 2009 ABCG2 paper was among the first to functionally characterize a GWAS-discovered transporter and attribute a common polymorphism to gout causality — highly influential (745 citations). Adoption of TabPFN machine learning for kidney cell-line assignment (2026) shows continued methodological frontiersmanship, though it builds on existing tools rather than inventing a new paradigm.



    Scientific Rigor

    80%

    Evidence units show controlled experiments (water-injected oocyte controls, S187T loss-of-function mutant, FTC inhibition), multivariable-adjusted population models, conservative PAR calculations using prevalence ratios, and negative controls in the 2026 study. Deductions: gout self-report without adjudication, low MAF (3%) in black participants requiring genotype pooling, functional work absent from native human proximal tubule, and cross-dataset ML accuracy only ~56–59%.

     Analysis Wizard



    Aggregating bulk RNA-seq profiles of kidney cell lines and matching them to pseudobulk single-cell kidney references using marker-gene correlation and TabPFN classification to validate cell-type assignments.



     Hypothesis Graveyard



    ABCG2 as the sole major urate transporter: falsified by the same author's later identification of a URAT1 loss-of-function allele in African Americans, showing multiple transporters contribute additively to serum urate.


    Cystogenesis driven purely by ciliary mechanosensation: superseded by Köttgen's own extra-ciliary polycystin roles (Ezrin regulation, lysosomal/calpain pathways, ER Ca2+), which reframed PKD as a multi-compartment trafficking and signaling disease.

     Science Art


    Author Review: Michael Köttgen Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($64 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT